HighTower Advisors’s Abiomed Inc ABMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-13,014
Closed -$3.15M 3598
2022
Q3
$3.15M Buy
13,014
+531
+4% +$143K 0.01% 1001
2022
Q2
$3.02M Buy
12,483
+101
+0.8% +$27.3K 0.01% 1041
2022
Q1
$4.1M Buy
12,382
+534
+5% +$164K 0.01% 997
2021
Q4
$4.28M Buy
11,848
+409
+4% +$138K 0.01% 982
2021
Q3
$3.75M Buy
11,439
+1,480
+15% +$501K 0.01% 942
2021
Q2
$3.05M Sell
9,959
-99
-1% -$30.4K 0.01% 1001
2021
Q1
$3.18M Sell
10,058
-1,556
-13% -$498K 0.01% 905
2020
Q4
$3.72M Buy
11,614
+3,444
+42% +$953K 0.02% 682
2020
Q3
$2.3M Sell
8,170
-1,028
-11% -$296K 0.01% 825
2020
Q2
$2.18M Buy
9,198
+940
+11% +$189K 0.01% 782
2020
Q1
$1.15M Buy
+8,258
New +$1.37M 0.01% 948
2019
Q4
Sell
-1,156
Closed -$205K 2583
2019
Q3
$205K Buy
1,156
+56
+5% +$12.1K ﹤0.01% 2047
2019
Q2
$287K Buy
1,100
+31
+3% +$8.22K ﹤0.01% 1829
2019
Q1
$306K Buy
1,069
+184
+21% +$61.2K ﹤0.01% 1711
2018
Q4
$287K Sell
885
-1,072
-55% -$372K ﹤0.01% 1635
2018
Q3
$871K Buy
1,957
+1,367
+232% +$539K 0.01% 1196
2018
Q2
$239K Buy
+590
New +$214K ﹤0.01% 1804

Other funds holding ABMD

HighTower Advisors's ABMD Position: Q4 2022 in Review

HighTower Advisors sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 13,014 shares — an estimated $3.15M sold.

HighTower Advisors first reported a position in ABMD in Q2 2018 and held it in 17 quarters. The position peaked at $4.28M in Q4 2021. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • HighTower Advisors reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • HighTower Advisors sold 13,014 Abiomed Inc shares in Q4 2022, an estimated $3.15M.
  • HighTower Advisors first reported a position in Abiomed Inc in Q2 2018 and held it in 17 quarters.
  • HighTower Advisors's Abiomed Inc position peaked at $4.28M in Q4 2021.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.